1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Guilin Sanjin Pharmaceutical Co., Ltd. Class A

Guilin Sanjin Pharmaceutical Co., Ltd. Class A

SSZSE:002275
12.11
CNY
+0.08
(+0.67%)
0.83EPS
14.63P/E
7.16BMarket Cap
Oct 28Next Earn
Guilin Sanjin Pharmaceutical Co., Ltd. Class A
SZSE:002275
(Shenzhen Stock Exchange)

Recent

price

12.11

P/E

ratio

14.63

div

yld

7.21%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.67
1.95
2.22
2.47
2.48
2.36
2.6
2.75
2.68
2.8
2.71
3.04
3.33
3.71
3.74
3.5
3.54
Revenue per Share
0.44
0.49
0.56
0.71
0.75
0.64
0.67
0.79
0.7
0.67
0.48
0.6
0.56
0.72
0.89
0.74
0.83
Basic EPS, GAAP
0.32
0.36
0.16
- -
0.31
0.47
0.8
0.59
0.78
0.41
0.68
0.46
0.79
0.81
0.86
1.06
- -
Free Cash Flow per Basic Share
0.43
0.17
0.4
0.5
0.55
0.61
0.5
0.41
0.4
0.36
0.25
0.79
0.97
0.73
0.57
0.58
0.87
Dividend per Share
3.04
3.36
3.52
3.75
3.93
4.04
4.11
4.5
4.76
4.77
5.01
4.81
4.79
4.79
5.12
5.43
5.56
Book Value per Share
2.76
3.09
3.23
3.42
3.62
3.71
3.79
4.19
4.45
4.47
4.71
4.5
4.49
4.52
4.87
5.19
5.32
Tangible Book Value per Share
588
596
591
594
590
588
588
588
590
585
577
573
588
585
586
585
589
Basic Weighted Avg Shares
983
1,162
1,312
1,469
1,466
1,391
1,525
1,616
1,585
1,640
1,566
1,741
1,960
2,172
2,194
2,046
2,084
Sales/Revenue/Turnover
30.43
29.18
29.47
31.9
34.07
28.92
29.51
33.36
31.45
28.45
21.45
23.55
20.84
23.72
26.1
27.77
32.15
Operating Margin (%)
26
27
28
30
35
61
65
69
76
91
80
107
115
115
110
99
- -
Depreciation Expense
259
292
331
422
445
377
394
464
413
392
277
344
330
421
522
433
491
Net Income, GAAP
18.71
20.06
18.5
18.14
16.25
14.46
17.91
17.51
16.61
16.14
19.51
19.89
26.14
18.71
19.01
19.33
17.34
Effective Tax Rate (%)
26.31
25.13
25.25
28.72
30.34
27.07
25.81
28.74
26.08
23.9
17.68
19.74
16.81
19.4
23.77
21.17
23.54
Profit Margin (%)
1,355
1,436
1,411
1,352
1,290
1,233
1,234
1,486
1,642
1,582
1,775
1,625
1,450
1,302
1,569
1,580
1,697
Working Capital
4
3
2
1
- -
- -
- -
- -
- -
75
336
315
206
135
150
207
251
LT Debt
1,800
1,983
2,078
2,211
2,321
2,386
2,426
2,654
2,807
2,815
2,959
2,840
2,813
2,817
3,010
3,191
3,264
Total Equity
13.8
15.14
15.79
18.14
18.67
14.86
15.36
17.37
14.28
13.09
8.75
9.85
9.64
12.49
14.85
11.8
13.17
Return on Invested Capital (%)
14.4
15.4
16.4
19.58
19.4
15.76
16.1
17.82
14.76
13.44
8.85
10.35
10.24
13.12
15.33
12.29
13.77
Return on Capital (%)
14.48
15.47
16.31
19.68
19.64
16
16.36
18.29
15.14
13.95
9.59
11.85
11.66
14.97
17.9
13.97
15.34
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
306
170
51
LT Borrowings
181
245
227
LT Finance Leases
27
25
24
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
588
588
588
Market Capitalization
8,285
8,508
7,162

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,364
2,535
2,130
Cash, Cash Equivalents & STI
1,721
1,739
1,398
Accounts Receivable, Net
82
322
219
Inventories
203
221
235
Total Current Liabilities
784
639
433
Payables & Accruals
- -
- -
- -
ST Debt
306
170
51
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.03%
1.61%
6.02%
Free Cash Flow
16.53%
14.84%
22.72%
Net Income, GAAP
3.17%
10.93%
-16.95%
Sales/Revenue/Turnover
4.15%
5.76%
-6.76%
Total Cash Common Dividend
11.13%
38%
1.46%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
483
586
506
619
2,194
2025
467
532
- -
583
2,046
2026
525
443
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.34
0.14
0.23
0.89
2025
0.18
0.31
- -
0.08
0.74
2026
0.21
0.23
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.3
- -
0.24
0.57
2025
0.01
0.36
- -
0.21
0.58
2026
0.01
0.3
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) engages in the research, development, production, and sale of traditional Chinese medicines and natural medicines primarily in China. Founded in 1967 and headquartered at No. 1 Jinxing Road in Guilin, Guangxi Zhuang Autonomous Region, the company operates as a subsidiary of Guilin Sanjin Group Co., Ltd. and maintains manufacturing facilities adhering to Good Manufacturing Practice standards. Its core products include the Sanjin Watermelon Frost series (Guilin Watermelon Frost, Watermelon Frost lozenges, Watermelon Frost throat tablets, and Watermelon Frost throat cleansing tablets) for throat, oral cavity, and dental conditions; Sanjin tablets for urinary tract infections, bladder inflammation, kidney inflammation, and prostate issues; Naomaitai (Naomai) capsules and Naomai tablets (also called Brain Pulse Tai capsules) for vertigo and dizziness; Yuye (Jade Leaf) detoxification granules for colds, coughs, laryngitis, sore throat, and urinary symptoms; Compound Tianqi stomach pain capsules for gastrointestinal discomfort; and additional proprietary Chinese medicine preparations covering respiratory, cardiovascular, and digestive health segments, with over 200 registered varieties and 47 exclusive formulations. The company targets domestic healthcare providers, pharmacies, hospitals, and consumers, with expanding international sales to over 30 countries in Southeast Asia, Europe, and Africa, driven by e-commerce channels accounting for around 30% of sales and partnerships with online platforms. Recent developments include recognition as a "Zhonghua Laozhao" (time-honored brand) in April 2024; Chairman Zou Xun receiving the National Labor Model award in May 2025; multiple marketing awards in 2024 and 2025 for Sanjin tablets and Watermelon Frost products, such as the 31st China International Advertising Festival Gold Case and China Innovation Communication Awards; profit growth in double digits for 2024 reported in April 2025; accelerated construction of the Sanjin Chinese Medicine City production warehouse expansion project as of July 2025; and ongoing R&D investments at approximately 10-12% of revenue, yielding new patents, product launches in oncology and chronic diseases, and clinical trials for innovative compounds through academic collaborations.